Repare Therapeutics to Introduce RP-6306, a Potent and Specific Inhibitor of a Novel Target, at Virtual Investor Day on April 8

Rhea-AI Summary

Repare Therapeutics (Nasdaq: RPTX) will host a virtual Investor Day on April 8, 2021, from 10:30 a.m. to 12:00 p.m. ET. The event will feature discussions on RP-6306, a novel inhibitor targeting CCNE1 amplification, with a Phase 1 clinical trial expected to commence in Q2 2021, a quarter ahead of prior guidance. The trial aims to evaluate safety and establish the recommended Phase 2 dose for patients with recurrent CCNE1 amplified tumors. Repare leverages its SNIPRx platform to develop targeted cancer therapies.

Positive

• RP-6306 trial commencement planned for Q2 2021, one quarter ahead of prior guidance.
• RP-6306 shows promising anti-tumor activity against tumors with CCNE1 amplification.

Negative

• None.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced it will host a virtual Investor Day on Thursday, April 8, 2021, from 10:30 a.m. to 12:00 p.m. Eastern Time. Repare Therapeutics’ executive management team will be joined by two distinguished physicians:

• Carol Aghajanian, MD, Chief, Gynecologic Medical Oncology Service, Professor of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, New York, NY

• Timothy Yap, MBBS, PhD, FRCP, Medical Director, Institute for Applied Cancer Science, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX

The event will focus on RP-6306, a potent and selective inhibitor of a novel target that is synthetic lethal with CCNE-1 amplification. The Company expects to begin a Phase 1 clinical trial in the second quarter of 2021, one quarter earlier than prior guidance.

To access the event virtual event, please dial (833) 638-9655 (U.S. and Canada) or (602) 585-9856 (international) at least 10 minutes prior to the start time and refer to conference ID 1093819. A live video webcast will be available in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A webcast replay will also be available on the corporate website at the conclusion of the call.

About RP-6306

RP-6306 is the result of Repare’s proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification, which typically do not respond well to platinum or PARP inhibitor treatment. Through Repare’s SNIPRx screen campaign for targets that are SL with CCNE1 amplification, the Company has identified and validated a novel SL gene that is believed to have the characteristics of a therapeutic target. Subsequently, the Company developed novel and selective inhibitors against the target that have repeatedly demonstrated compelling anti-tumor activity and announced the advancement of a clinical candidate for this potential first-in-class program. Repare anticipates initiating a Phase 1 clinical trial for RP-6306 in the second quarter of 2021. This trial is expected to enroll patients suffering from recurrent tumors characterized by CCNE1 amplification and other genomic alterations predicted to be sensitive to RP-6306. The primary objective of the trial is to establish the recommended Phase 2 dose and schedule for RP-6306 for further studies as monotherapy and to assess preliminary safety in patients. An additional trial is planned to evaluate combination with approved anticancer agents.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx^® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential best-in-class ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor, and a Polθ inhibitor program. For more information, please visit reparerx.com.

SNIPRx^® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210330006026/en/

FAQ

What is RP-6306 from Repare Therapeutics?

RP-6306 is a novel inhibitor targeting tumors with CCNE1 amplification, aiming to treat patients who typically do not respond to standard therapies.

When does the RP-6306 clinical trial start?

The Phase 1 clinical trial for RP-6306 is expected to begin in the second quarter of 2021.

What are the goals of the RP-6306 clinical trial?

The trial aims to establish the recommended Phase 2 dose and assess preliminary safety in patients with recurrent tumors exhibiting CCNE1 amplification.

What is the significance of the April 8, 2021 Investor Day?

The Investor Day will provide insights into RP-6306 and its development, along with participation from leading oncologists.

How does Repare Therapeutics discover its cancer therapies?

Repare utilizes its proprietary SNIPRx platform, a CRISPR-enabled approach, to identify and develop targeted cancer therapies.